ibrutinib
Janssen,Abbvie
['ibru', 'lymsm', 'cll']
#eha2023 | petra langerbeins shares the final results of the cll12 trial on ibrutinib in treatment-na ve early stage cll. orr 72.5%, median os not reached. ibrutinib failed to demonstrate survival benefit compared with placebo. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm